Hannah L Rhodes1, Laura Yarram-Smith2, Sarah J Rice3, Ayla Tabaksert3, Noel Edwards4, Alice Hartley5, Mark N Woodward1, Sarah L Smithson6, Charles Tomson7, Gavin I Welsh1, Margaret Williams2, David T Thwaites3, John A Sayer8, Richard J M Coward1. 1. Academic and Children's Renal Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom; 2. Bristol Genetics Laboratory-Pathology Sciences and. 3. Institute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom; 4. Institute of Genetic Medicine, International Centre for Life and. 5. Department of Urology, National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom; 6. Department of Clinical Genetics, University Hospitals, Bristol, United Kingdom; and. 7. Richard Bright Renal Unit, Southmead Hospital, Bristol, United Kingdom; Department of Renal Medicine, Freeman Hospital, Newcastle upon Tyne, United Kingdom. 8. Institute of Genetic Medicine, International Centre for Life and Department of Renal Medicine, Freeman Hospital, Newcastle upon Tyne, United Kingdom John.Sayer@ncl.ac.uk Richard.Coward@bristol.ac.uk.
Abstract
BACKGROUND AND OBJECTIVES: Cystinuria is a rare inherited renal stone disease. Mutations in the amino acid exchanger System b(0,+), the two subunits of which are encoded by SLC3A1 and SLC7A9, predominantly underlie this disease. The work analyzed the epidemiology of cystinuria and the influence of mutations in these two genes on disease severity in a United Kingdom cohort. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Prevalent patients were studied from 2012 to 2014 in the northeast and southwest of the United Kingdom. Clinical phenotypes were defined, and genetic analysis of SLC3A1 and SLC7A9 combining Sanger sequencing and multiplex ligation probe-dependent amplification was performed. RESULTS: In total, 76 patients (42 men and 34 women) were studied. All subjects had proven cystine stones. Median age of presentation (first stone episode) was 24 years old, but 21% of patients presented after 40 years old. Patients had varied clinical courses, with 37% of patients having ≥10 stone episodes; 70% had evidence of CKD, and 9% had reached ESRD as a result of cystinuria and its complications. Patients with cystinuria received a variety of different therapies, with no obvious treatment consensus. Notably, 20% of patients had staghorn calculi, with associated impaired renal function in 80% of these patients. Genetic analysis revealed that biallelic mutations were present in either SLC3A1 (n=27) or SLC7A9 (n=20); 22 patients had only one mutated allele detected (SLC3A1 in five patients and SLC7A9 in 17 patients). In total, 37 different mutant variant alleles were identified, including 12 novel mutations; 22% of mutations were caused by large gene rearrangements. No genotype-phenotype association was detected in this cohort. CONCLUSIONS: Patients with cystinuria in the United Kingdom often present atypically with staghorn calculi at ≥40 years old and commonly develop significant renal impairment. There is no association of clinical course with genotype. Treatments directed toward reducing stone burden need to be rationalized and developed to optimize patient care.
BACKGROUND AND OBJECTIVES:Cystinuria is a rare inherited renal stone disease. Mutations in the amino acid exchanger System b(0,+), the two subunits of which are encoded by SLC3A1 and SLC7A9, predominantly underlie this disease. The work analyzed the epidemiology of cystinuria and the influence of mutations in these two genes on disease severity in a United Kingdom cohort. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Prevalent patients were studied from 2012 to 2014 in the northeast and southwest of the United Kingdom. Clinical phenotypes were defined, and genetic analysis of SLC3A1 and SLC7A9 combining Sanger sequencing and multiplex ligation probe-dependent amplification was performed. RESULTS: In total, 76 patients (42 men and 34 women) were studied. All subjects had proven cystine stones. Median age of presentation (first stone episode) was 24 years old, but 21% of patients presented after 40 years old. Patients had varied clinical courses, with 37% of patients having ≥10 stone episodes; 70% had evidence of CKD, and 9% had reached ESRD as a result of cystinuria and its complications. Patients with cystinuria received a variety of different therapies, with no obvious treatment consensus. Notably, 20% of patients had staghorn calculi, with associated impaired renal function in 80% of these patients. Genetic analysis revealed that biallelic mutations were present in either SLC3A1 (n=27) or SLC7A9 (n=20); 22 patients had only one mutated allele detected (SLC3A1 in five patients and SLC7A9 in 17 patients). In total, 37 different mutant variant alleles were identified, including 12 novel mutations; 22% of mutations were caused by large gene rearrangements. No genotype-phenotype association was detected in this cohort. CONCLUSIONS:Patients with cystinuria in the United Kingdom often present atypically with staghorn calculi at ≥40 years old and commonly develop significant renal impairment. There is no association of clinical course with genotype. Treatments directed toward reducing stone burden need to be rationalized and developed to optimize patient care.
Authors: M Barbosa; A Lopes; C Mota; E Martins; J Oliveira; S Alves; P De Bonis; M do Céu Mota; C Dias; P Rodrigues-Santos; A M Fortuna; D Quelhas; L Lacerda; L Bisceglia; M L Cardoso Journal: Clin Genet Date: 2011-02-14 Impact factor: 4.438
Authors: L Feliubadaló; M Font; J Purroy; F Rousaud; X Estivill; V Nunes; E Golomb; M Centola; I Aksentijevich; Y Kreiss; B Goldman; M Pras; D L Kastner; E Pras; P Gasparini; L Bisceglia; E Beccia; M Gallucci; L de Sanctis; A Ponzone; G F Rizzoni; L Zelante; M T Bassi; A L George; M Manzoni; A De Grandi; M Riboni; J K Endsley; A Ballabio; G Borsani; N Reig; E Fernández; R Estévez; M Pineda; D Torrents; M Camps; J Lloberas; A Zorzano; M Palacín Journal: Nat Genet Date: 1999-09 Impact factor: 38.330
Authors: Juan Alberto Piñero-Fernández; Carmen Vicente-Calderón; María José Lorente-Sánchez; María Jesús Juan-Fita; José María Egea-Mellado; Inmaculada C González-Gallego Journal: Pediatr Nephrol Date: 2022-10-13 Impact factor: 3.651
Authors: Viola D'Ambrosio; Giovanna Capolongo; David Goldfarb; Giovanni Gambaro; Pietro Manuel Ferraro Journal: Pediatr Nephrol Date: 2021-11-23 Impact factor: 3.651
Authors: Ji Hyun Kim; Eujin Park; Hye Sun Hyun; Beom Hee Lee; Gu Hwan Kim; Joo Hoon Lee; Young Seo Park; Hee Gyung Kang; Il Soo Ha; Hae Il Cheong Journal: J Korean Med Sci Date: 2017-02 Impact factor: 2.153
Authors: Marcin Tkaczyk; Katarzyna Gadomska-Prokop; Iga Załuska-Leśniewska; Kinga Musiał; Jan Zawadzki; Katarzyna Jobs; Tadeusz Porowski; Anna Rogowska-Kalisz; Anna Jander; Meritrafat Kirolos; Adam Haliński; Aleksandra Krzemień; Agnieszka Sobieszczańska-Droździel; Katarzyna Zachwieja; Bodo B Beck; Przemysław Sikora; Marcin Zaniew Journal: Ren Fail Date: 2021-12 Impact factor: 2.606